A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome
NCT ID: NCT00349284
Last Updated: 2007-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
181 participants
INTERVENTIONAL
2005-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Combination of 145 mg fenofibrate and 10 mg ezetimibe
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Solvay Pharmaceuticals
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Director Solvay
Role: STUDY_DIRECTOR
Solvay Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 113
Charleroi, , Belgium
Site 111
Comines, , Belgium
Site 112
Couillet, , Belgium
Site 115
Dessel, , Belgium
Site 114
Dour, , Belgium
Site 106
Genk, , Belgium
Site 102
Genly, , Belgium
Site 109
Kortessem, , Belgium
Site 104
Kortrijk, , Belgium
Site 108
Liège, , Belgium
Site 107
Menen, , Belgium
Site 105
Moen, , Belgium
Site 101
Oosteeklo, , Belgium
Site 110
Oostham, , Belgium
Site 116
Seraing, , Belgium
Site 103
Turnhout, , Belgium
Site 213
Bondy, , France
Site 211
Le Beausset, , France
Site 209
Nantes, , France
Site 202
Orvault, , France
Site 206
Paris, , France
Site 208
Paris, , France
Site 212
Paris, , France
Site 201
Saint Sébastian Sur Loire, , France
Site 205
Saint Sébastian Sur Loire, , France
Site 207
Saint Sébastian Sur Loire, , France
Site 203
Saint-Cyr, , France
Site 210
Six-Fours-les-Plages, , France
Site 204
Toulon, , France
Site 313
Borna, , Germany
Site 307
Bretten, , Germany
Site 306
Dresden, , Germany
Site 305
Erbach im Odenwald, , Germany
Site 304
Frankfurt, , Germany
Site 308
Frankfurt, , Germany
Site 311
Frankfurt, , Germany
Site 301
Ilvesheim, , Germany
Site 302
Leipzig, , Germany
Site 303
Leipzig, , Germany
Site 314
Mannheim, , Germany
Site 309
Offenbach, , Germany
Site 312
Offenbach, , Germany
Site 310
Rodgau, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A; Study Investigators. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. Am J Cardiovasc Drugs. 2009;9(2):91-101. doi: 10.1007/BF03256580.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2004-002408-13
Identifier Type: -
Identifier Source: secondary_id
C LF 178P 04 01
Identifier Type: -
Identifier Source: org_study_id